Skip to content

COMPARISON OF A LOCALLY DEVELOPED READY-TO-USE- THERAPEUTIC FOODS COMPARED WITH THE IMPORTED READY-TO-USE- THERAPEUTIC FOODS AMONG UNDER-FIVE CHILDREN WITH SEVERE ACUTE MALNUTRITION IN

FEDERAL INSTITUTE OF INDUSTRIAL RESEARCH OSHODI-DEVELOPED READY-TO-USE- THERAPEUTIC FOODS (FIIRO-RUTF) FOR THE MANAGEMENT OF SEVERE ACUTE MALNUTRITION IN UNDER-FIVE CHILDREN AT TWO MAJOR HOSPITALS IN ABEOKUTA NIGERIA

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
PACTR
Registry ID
PACTR202206718379355
Enrollment
214
Registered
2022-06-23
Start date
2022-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional, Metabolic, Endocrine Paediatrics

Interventions

Federal Institute of industrial Research Osodi Ready to use therapeutic food FIIRO RUTF

Sponsors

Federal Insitute of Industrial Research Oshodi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Children aged 6 months to 5 year 2. Patients with SAM irrespective of retroviral status (weight-for-height z-score of <-3 or a Mid-Upper Arm Circumference (MUAC) of <115 mm or the presence of bilateral pitting edema, or both in children 6 to 59 months of age) 3. Consent by parents or guardians.

Exclusion criteria

Exclusion criteria: 1. Children with emergency or life-threatening conditions like heart failure 2. Children with a significant congenital abnormality or underlying clinical conditions such as congenital heart disease and chronic kidney disease.

Design outcomes

Primary

MeasureTime frame
1.Recovery-reaching a WHZ score > -2, 2.Acceptability defined as Acceptable if child eat >50% of the offered product of good acceptability if >75% of the product is consumed,17 3.Relapsed defined as admission to inpatient therapeutic care during the study period, 4.Death

Secondary

MeasureTime frame
1. Weight gain and increase in MUAC 2. Time to recovery 3. Presence of diarrhoea in the first 2 weeks of treatment

Countries

Nigeria

Contacts

Public ContactMorufat Ogundeyi

Chief onsultant Paediatrician Federal Medical Centre ABeokuta Ogun State Nigeria

drmorufat@yahoo.com+2348136572721

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026